| 摘要 |
PURPOSE: Provided is a clinical method of migraine in mammals including a human by administering a therapeutic composition of a 5HT1 receptor agonist and either a cyclooxygenase-2(COX-2) Inhibitor or a nonsteroidalantiinflammatory drug(NSAID). CONSTITUTION: The pharmaceutical composition comprises: a 5HT1 receptor agonist (preferably selected from eletriptan, rizatriptan, zolmitriptan, sumatriptan and naratriptan); either a cyclooxygenase 2 inhibitor or a nonsteroid anti-inflammatory drug (preferably selected from diclofenac sodium, nabumetone, naproxen sodium, ketorolac and ibuprofen; and a pharmaceutically acceptable carrier. Preferably the effective dose of 5HT1 receptor agonist is about 0.05-about 100 mg/day and that of COX-2 or NSAID is about 10-300 mg/day or 15-2,000 mg/day respectively.
|
